Agilent Technologies, Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
What does it do?
Agilent makes the tools that scientists use to study biology, test chemicals, and diagnose diseases. Think of them as the company that builds the machines inside laboratories — like a high-tech microscope company, but for chemistry and genetics. For example, if a pharmaceutical company wants to check that a drug is pure before selling it, they likely use Agilent equipment to do it. Their instruments show up in hospitals, universities, food safety labs, and drug factories around the world.
Agilent sits at the center of two massive trends: the explosion in drug development (especially biologics and gene therapies) and the growing demand for food and environmental safety testing. As governments tighten regulations on everything from pesticides to pharmaceuticals, labs need more precise equipment — and Agilent is one of the few companies that can supply it at scale. Right now, investors are watching closely because a slowdown in biotech funding has weighed on Agilent's sales, making this a potential recovery story.
How does it make money?
Agilent makes money across three business lines. The biggest is Life Sciences and Diagnostics, which sells lab instruments like liquid chromatography systems — machines that separate and identify the components of a substance — and generates the bulk of the company's $6.9 billion in annual revenue. The second segment, Agilent CrossLab, is a services and consumables business: labs need to keep buying supplies and maintenance contracts, which creates steady, recurring income. The third, Applied Markets, sells to food testing and environmental labs. Net income came in at $1.3 billion last year, meaning Agilent keeps roughly 19 cents of profit for every dollar it earns.
Why do investors care?
The long-term growth story is simple: more drugs being developed means more lab equipment needed. Agilent grew revenue from $6.5 billion to $6.9 billion year-over-year, a roughly 6% increase, but recent quarters have been bumpier as biotech companies cut spending. The bull case is that this slowdown is temporary and Agilent emerges stronger as a key supplier to the booming GLP-1 drug market (think Ozempic) and next-generation cancer therapies. For this story to work, biotech spending needs to recover and Agilent's recurring services revenue needs to keep growing.
Deep Dive
MemberA full investor briefing on Agilent Technologies, Inc. — history, leadership, risks, and outlook.